Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma

• Published in: Pediatrics (Evanston) Vol. 142; no. 3
• Main Authors: Baselga, Eulalia, Dembowska-Baginska, Bozenna, Przewratil, Przemysław, González-Enseñat, María Antonia, Wyrzykowski, Dariusz, Torrelo, Antonio, López Gutiérrez, Juan-Carlos, Rychłowska-Pruszyńska, Magdalena, de Lucas-Laguna, Raúl, Esteve-Martinez, Altea, Roé, Esther, Zaim, Mohammed, Menon, Yoann, Gautier, Stéphanie, Lebbé, Geneviève, Bouroubi, Athmane, Delarue, Alain, Voisard, Jean-Jacques
• Format: Journal Article
• Language: English
• Published: United States 01.09.2018
• Subjects: Administration, Oral; Adrenergic beta-Antagonists - administration & dosage; Drug Administration Schedule; Female; Hemangioma - diagnosis; Hemangioma - drug therapy; Humans; Infant; Male; Propranolol - administration & dosage; Risk Factors; Treatment Outcome
• ISSN: 1098-4275
• DOI: 10.1542/peds.2017-3866

There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH). We evaluated the efficacy and safety of oral propranolol solution administered for a minimum of 6 months up to a maximum of 12 months of age in high-risk IH. This single-arm, open-label, phase 3 study was conducted in patients aged 35 to 150 days with high-risk IH in 10 hospitals between 2015 and 2017. The study comprised a 6-month initial treatment period (ITP) plus continuation up to 12 months of age if complete success was not achieved, a follow-up, and a retreatment period. Patients received oral propranolol twice daily (3 mg/kg per day). The primary end point was the success rate at the end of the ITP. Furthermore, the persistence of IH response and efficacy of retreatment was evaluated. The success rate after 6 months of treatment was 47%, increasing to 76% at the end of the ITP. Of the patients who achieved success, 68% sustained success for 3 months without treatment, and 24% required retreatment. Of the 8 patients who were retreated, 7 achieved success. Adverse events, reported by 80% of patients, were mild, which were expected in this population or known propranolol side effects. Oral propranolol administered beyond 6 months and up to 12 months of age meaningfully increases the success rate in high-risk IH. Success was sustained in most patients up to 3 months after stopping treatment. Retreatment was efficacious, and the safety profile satisfactory.